RU2018124600A3 - - Google Patents

Download PDF

Info

Publication number
RU2018124600A3
RU2018124600A3 RU2018124600A RU2018124600A RU2018124600A3 RU 2018124600 A3 RU2018124600 A3 RU 2018124600A3 RU 2018124600 A RU2018124600 A RU 2018124600A RU 2018124600 A RU2018124600 A RU 2018124600A RU 2018124600 A3 RU2018124600 A3 RU 2018124600A3
Authority
RU
Russia
Application number
RU2018124600A
Other languages
Russian (ru)
Other versions
RU2759679C2 (ru
RU2018124600A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018124600A3 publication Critical patent/RU2018124600A3/ru
Publication of RU2018124600A publication Critical patent/RU2018124600A/ru
Application granted granted Critical
Publication of RU2759679C2 publication Critical patent/RU2759679C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2018124600A 2015-12-08 2016-12-08 Применение вариантов натрийуретического пептида типа с для лечения остеоартрита RU2759679C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562264682P 2015-12-08 2015-12-08
US62/264,682 2015-12-08
PCT/US2016/065520 WO2017100400A2 (en) 2015-12-08 2016-12-08 Use of c-type natriuretic peptide variants to treat osteoarthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2021132347A Division RU2850341C2 (ru) 2015-12-08 2016-12-08 Применение вариантов натрийуретического пептида типа c для лечения остеоартрита

Publications (3)

Publication Number Publication Date
RU2018124600A3 true RU2018124600A3 (enExample) 2020-01-13
RU2018124600A RU2018124600A (ru) 2020-01-13
RU2759679C2 RU2759679C2 (ru) 2021-11-16

Family

ID=59013378

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018124600A RU2759679C2 (ru) 2015-12-08 2016-12-08 Применение вариантов натрийуретического пептида типа с для лечения остеоартрита

Country Status (17)

Country Link
US (2) US11202819B2 (enExample)
EP (2) EP4019038A3 (enExample)
JP (1) JP7104625B2 (enExample)
KR (1) KR102941538B1 (enExample)
CN (1) CN108697766A (enExample)
AU (2) AU2016365751B2 (enExample)
CA (1) CA3007315A1 (enExample)
DK (1) DK3386531T3 (enExample)
ES (1) ES2901769T3 (enExample)
HR (1) HRP20211908T1 (enExample)
HU (1) HUE057083T2 (enExample)
IL (1) IL259690B2 (enExample)
MX (1) MX2018006986A (enExample)
PL (1) PL3386531T3 (enExample)
PT (1) PT3386531T (enExample)
RU (1) RU2759679C2 (enExample)
WO (1) WO2017100400A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017205693B2 (en) 2016-01-08 2022-03-31 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low initial NPR-B activity
JP6968802B2 (ja) 2016-01-08 2021-11-17 アセンディス ファーマ グロース ディスオーダーズ エー/エス 環部分にキャリア結合を有するcnpプロドラッグ
CA3008015A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release c-type natriuretic peptide agonists with increased neutral endopeptidase stability
EP4710947A3 (en) 2016-01-08 2026-06-17 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
KR102518217B1 (ko) 2016-01-08 2023-04-04 아센디스 파마 그로우쓰 디스오더스 에이/에스 낮은 npr-c 결합을 갖는 제어 방출성 cnp 작용제
US10835578B2 (en) 2016-01-08 2020-11-17 Ascendis Pharma Growth Disorders A/S CNP prodrugs with large carrier moieties
RU2768747C2 (ru) 2016-09-29 2022-03-24 Асцендис Фарма Гроус Дизордерс А/С Комбинаторная терапия с агонистами cnp контролируемого высвобождения
CN112752556A (zh) * 2018-04-27 2021-05-04 雷米生物科学公司 新的医疗装置、递送运载体及其制造
EP3923906A1 (en) * 2019-02-11 2021-12-22 Ascendis Pharma Growth Disorders A/S Dry pharmaceutical formulations of cnp conjugates
CN116635027A (zh) * 2020-11-25 2023-08-22 普罗林科斯有限责任公司 C-利钠肽的延长释放水凝胶偶联物
WO2022240936A1 (en) * 2021-05-11 2022-11-17 Texas Tech University System Targeted selenium conjugates as countermeasures for pathogenic viruses and cells
CA3242257A1 (en) * 2021-12-07 2023-06-15 Biomarin Pharmaceutical Inc. C-type natriuretic peptide therapy of bone-related disorders
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
KR102866559B1 (ko) 2022-11-02 2025-10-02 노보 노르디스크 에이/에스 Cnp 화합물
KR20250162619A (ko) 2023-03-20 2025-11-18 아센디스 파마 그로우쓰 디스오더스 에이/에스 연골무형성증을 가진 인간 대상에서의 흉요추 변형의 치료 방법
KR20250098109A (ko) * 2023-12-21 2025-07-01 주식회사 펩트론 나트륨이뇨 펩타이드 유사체 및 이의 용도
CN117801123B (zh) * 2024-02-29 2024-05-03 天津凯莱英生物科技有限公司 沃索利肽可溶性中间体、中间体制备方法及沃索利肽的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
JP2809533B2 (ja) 1991-01-31 1998-10-08 壽之 松尾 Cnp類似体ペプチド
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
KR20070007842A (ko) * 2004-03-31 2007-01-16 카즈와 나카오 신장증가용 조성물
ES2465141T3 (es) * 2004-03-31 2014-06-05 Kazuwa Nakao Remedio o medicamento preventivo para la artritis
AR069409A1 (es) 2007-11-21 2010-01-20 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
EP2432489B1 (en) 2009-05-20 2016-10-05 BioMarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
JP6055779B2 (ja) * 2010-12-27 2016-12-27 アレクシオン ファーマシューティカルズ, インコーポレイテッド ナトリウム利尿ペプチドを含む組成物およびその使用方法

Also Published As

Publication number Publication date
AU2016365751A1 (en) 2018-06-21
RU2021132347A (ru) 2022-03-24
EP4019038A2 (en) 2022-06-29
CA3007315A1 (en) 2017-06-15
PL3386531T3 (pl) 2022-02-28
AU2016365751B2 (en) 2023-12-21
RU2759679C2 (ru) 2021-11-16
PT3386531T (pt) 2021-12-29
KR20180088459A (ko) 2018-08-03
US11202819B2 (en) 2021-12-21
IL259690B (en) 2022-10-01
US12214015B2 (en) 2025-02-04
EP3386531B1 (en) 2021-10-13
ES2901769T3 (es) 2022-03-23
RU2018124600A (ru) 2020-01-13
AU2024201852A1 (en) 2024-04-11
WO2017100400A3 (en) 2017-10-26
EP3386531A2 (en) 2018-10-17
US20190247467A1 (en) 2019-08-15
EP4019038A3 (en) 2022-09-28
JP7104625B2 (ja) 2022-07-21
CN108697766A (zh) 2018-10-23
MX2018006986A (es) 2018-09-05
WO2017100400A2 (en) 2017-06-15
HRP20211908T1 (hr) 2022-03-04
JP2019505486A (ja) 2019-02-28
KR102941538B1 (ko) 2026-03-19
IL259690A (en) 2018-07-31
DK3386531T3 (da) 2022-01-03
HUE057083T2 (hu) 2022-04-28
US20220160836A1 (en) 2022-05-26
IL259690B2 (en) 2023-02-01

Similar Documents

Publication Publication Date Title
BR112018005587A2 (enExample)
AU2022228198B1 (enExample)
CN303067240S (zh) 包装盒(108片妇科千金片)
CN303066834S (zh) 酒瓶(帝聚堂)
CN303068557S (zh) 梯级用前挡板
BE2015C047I2 (enExample)
BR0009349B1 (enExample)
BR0001810B1 (enExample)
BR0008789B1 (enExample)
BR0009761B1 (enExample)
BR0008874B1 (enExample)
BR0001536B1 (enExample)
BR0009717B1 (enExample)
BR9916507B1 (enExample)
BR0009182B1 (enExample)
BR0002874B1 (enExample)
BR0007834B1 (enExample)
BR0009994B1 (enExample)
BR0007487B1 (enExample)
BR0000695B1 (enExample)
BR0000126B1 (enExample)
BR0003401B1 (enExample)
BR0006854B1 (enExample)
BR0009649B1 (enExample)
BR0002802B1 (enExample)